{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:06:33Z","timestamp":1790708793102,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ocular and urogenital infections with<jats:italic>Chlamydia trachomatis (C.t<\/jats:italic>.) are caused by a range of different serovars. The first<jats:italic>C.t<\/jats:italic>. vaccine in clinical development (CTH522\/CAF\u00ae01) induced neutralizing antibodies directed to the variable domain 4 (VD4) region of major outer membrane protein (MOMP), covering predominantly B and intermediate groups of serovars. The VD1 region of MOMP contains neutralizing B-cell epitopes targeting serovars of the C and C-related complex. Using an immuno-repeat strategy, we extended the VD1 region of SvA and SvJ to include surrounding conserved segments, extVD1<jats:sup>A<\/jats:sup>and extVD1<jats:sup>J<\/jats:sup>, and repeated this region four times. The extVD1<jats:sup>A<\/jats:sup>*4 was most immunogenic with broad cross-surface and neutralizing reactivity against representative members of the C and C-related complex serovars. Importantly, in vitro results for extVD1<jats:sup>A<\/jats:sup>*4 translated into in vivo biological effects, demonstrated by in vivo neutralization of SvA and protection\/cross-protection against intravaginal challenge with both SvA and the heterologous SvIa strain.<\/jats:p>","DOI":"10.1038\/s41541-021-00312-9","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T10:10:06Z","timestamp":1618827006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C\/C-related complex serovars"],"prefix":"10.1038","volume":"6","author":[{"given":"Anja Weinreich","family":"Olsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Rosenkrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-6318","authenticated-orcid":false,"given":"Martin J.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8373-7774","authenticated-orcid":false,"given":"Frank","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"312_CR1","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/S0140-6736(13)62182-0","volume":"384","author":"HR Taylor","year":"2014","unstructured":"Taylor, H. R., Burton, M. J., Haddad, D., West, S. & Wright, H. Trachoma. Lancet 384, 2142\u20132152 (2014).","journal-title":"Lancet"},{"key":"312_CR2","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2217\/fmb.13.80","volume":"8","author":"H Abdelsamed","year":"2013","unstructured":"Abdelsamed, H., Peters, J. & Byrne, G. I. Genetic variation in Chlamydia trachomatis and their hosts: impact on disease severity and tissue tropism. Future Microbiol. 8, 1129\u20131146 (2013).","journal-title":"Future Microbiol."},{"key":"312_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/infdis\/jiv137","volume":"212","author":"AW Olsen","year":"2015","unstructured":"Olsen, A. W., Follmann, F., Erneholm, K., Rosenkrands, I. & Andersen, P. Protection against Chlamydia trachomatis Infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. J. Infect. Dis. 212, 978\u2013989 (2015).","journal-title":"J. Infect. Dis."},{"key":"312_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/oxfordjournals.aje.a120654","volume":"84","author":"C Dawson","year":"1966","unstructured":"Dawson, C. et al. Experimental inclusion conjunctivitis in man. II. Partial resistance to reinfection. Am. J. Epidemiol. 84, 411\u2013425 (1966).","journal-title":"Am. J. Epidemiol."},{"key":"312_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1084\/jem.115.5.1009","volume":"115","author":"JT Grayston","year":"1962","unstructured":"Grayston, J. T., Wang, S. P., Yang, Y. F. & Woolridge, R. L. The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J. Exp. Med. 115, 1009\u20131022 (1962).","journal-title":"J. Exp. Med."},{"key":"312_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jama.1965.03090190042012","volume":"194","author":"E Jawetz","year":"1965","unstructured":"Jawetz, E., Rose, L., Hanna, L. & Thygeson, P. Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA 194, 620\u2013632 (1965).","journal-title":"JAMA"},{"key":"312_CR7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4049\/jimmunol.113.5.1607","volume":"113","author":"J Barenfanger","year":"1974","unstructured":"Barenfanger, J. & MacDonald, A. B. The role of immunoglobulin in the neutralization of trachoma infectivity. J. Immunol. 113, 1607\u20131617 (1974).","journal-title":"J. Immunol."},{"key":"312_CR8","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/0002-9394(67)94155-4","volume":"63","author":"SP Wang","year":"1967","unstructured":"Wang, S. P., Grayston, J. T. & Alexander, E. R. Trachoma vaccine studies in monkeys. Am. J. Ophthalmol. 63, 1615\u20131630 (1967).","journal-title":"Am. J. Ophthalmol."},{"key":"312_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00133785","volume":"12","author":"SP Wang","year":"1988","unstructured":"Wang, S. P. & Grayston, J. T. Micro-immunofluorescence antibody responses to trachoma vaccines. Int. Ophthalmol. 12, 73\u201380 (1988).","journal-title":"Int. Ophthalmol."},{"key":"312_CR10","unstructured":"Schachter, J. in Chlamydia - Intracellular Biology, Pathogenesis, and Immunity (ed R. S. Stephens) Ch. 6 (1999)."},{"key":"312_CR11","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1110\/ps.3650102","volume":"11","author":"MJ Rodriguez-Maranon","year":"2002","unstructured":"Rodriguez-Maranon, M. J., Bush, R. M., Peterson, E. M., Schirmer, T. & de la Maza, L. M. Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia. Protein Sci. 11, 1854\u20131861 (2002).","journal-title":"Protein Sci."},{"key":"312_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/infdis\/152.4.791","volume":"152","author":"SP Wang","year":"1985","unstructured":"Wang, S. P., Kuo, C. C., Barnes, R. C., Stephens, R. S. & Grayston, J. T. Immunotyping of Chlamydia trachomatis with monoclonal antibodies. J. Infect. Dis. 152, 791\u2013800 (1985).","journal-title":"J. Infect. Dis."},{"key":"312_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1128\/iai.57.4.1040-1049.1989","volume":"57","author":"Y Yuan","year":"1989","unstructured":"Yuan, Y., Zhang, Y. X., Watkins, N. G. & Caldwell, H. D. Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars. Infect. Immun. 57, 1040\u20131049 (1989).","journal-title":"Infect. Immun."},{"key":"312_CR14","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1128\/iai.59.11.4147-4153.1991","volume":"59","author":"EM Peterson","year":"1991","unstructured":"Peterson, E. M., Cheng, X., Markoff, B. A., Fielder, T. J. & de la Maza, L. M. Functional and structural mapping of Chlamydia trachomatis species-specific major outer membrane protein epitopes by use of neutralizing monoclonal antibodies. Infect. Immun. 59, 4147\u20134153 (1991).","journal-title":"Infect. Immun."},{"key":"312_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1128\/iai.31.3.1161-1176.1981","volume":"31","author":"HD Caldwell","year":"1981","unstructured":"Caldwell, H. D., Kromhout, J. & Schachter, J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31, 1161\u20131176 (1981).","journal-title":"Infect. Immun."},{"key":"312_CR16","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.1128\/IAI.69.10.6240-6247.2001","volume":"69","author":"S Pal","year":"2001","unstructured":"Pal, S., Theodor, I., Peterson, E. M. & de la Maza, L. M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69, 6240\u20136247 (2001).","journal-title":"Infect. Immun."},{"key":"312_CR17","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S0264-410X(02)00680-1","volume":"21","author":"S Pal","year":"2003","unstructured":"Pal, S., Luke, C. J., Barbour, A. G., Peterson, E. M. & de la Maza, L. M. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21, 1455\u20131465 (2003).","journal-title":"Vaccine"},{"key":"312_CR18","doi-asserted-by":"publisher","first-page":"8153","DOI":"10.1128\/IAI.73.12.8153-8160.2005","volume":"73","author":"S Pal","year":"2005","unstructured":"Pal, S., Peterson, E. M. & de la Maza, L. M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73, 8153\u20138160 (2005).","journal-title":"Infect. Immun."},{"key":"312_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.vaccine.2005.08.074","volume":"24","author":"S Pal","year":"2006","unstructured":"Pal, S., Peterson, E. M., Rappuoli, R., Ratti, G. & de la Maza, L. M. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 24, 766\u2013775 (2006).","journal-title":"Vaccine"},{"key":"312_CR20","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1016\/j.vaccine.2009.05.008","volume":"27","author":"G Sun","year":"2009","unstructured":"Sun, G., Pal, S., Weiland, J., Peterson, E. M. & de la Maza, L. M. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 27, 5020\u20135025 (2009).","journal-title":"Vaccine"},{"key":"312_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1086\/590670","volume":"198","author":"J Hansen","year":"2008","unstructured":"Hansen, J. et al. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis. 198, 758\u2013767 (2008).","journal-title":"J. Infect. Dis."},{"key":"312_CR22","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1128\/IAI.00734-12","volume":"81","author":"DF Tifrea","year":"2013","unstructured":"Tifrea, D. F., Ralli-Jain, P., Pal, S. & de la Maza, L. M. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect. Immun. 81, 1741\u20131750 (2013).","journal-title":"Infect. Immun."},{"key":"312_CR23","doi-asserted-by":"publisher","first-page":"7659","DOI":"10.1016\/j.vaccine.2010.09.040","volume":"28","author":"P Ralli-Jain","year":"2010","unstructured":"Ralli-Jain, P., Tifrea, D., Cheng, C., Pal, S. & de la Maza, L. M. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine 28, 7659\u20137666 (2010).","journal-title":"Vaccine"},{"key":"312_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/infdis\/jiz438","volume":"221","author":"DF Tifrea","year":"2020","unstructured":"Tifrea, D. F., Pal, S. & de la Maza, L. M. A Recombinant Chlamydia trachomatis MOMP vaccine elicits cross-serogroup protection in mice against vaginal shedding and infertility. J. Infect. Dis. 221, 191\u2013200 (2020).","journal-title":"J. Infect. Dis."},{"key":"312_CR25","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1128\/JB.00552-07","volume":"189","author":"G Sun","year":"2007","unstructured":"Sun, G. et al. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J. Bacteriol. 189, 6222\u20136235 (2007).","journal-title":"J. Bacteriol."},{"key":"312_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068934","volume":"8","author":"VA Feher","year":"2013","unstructured":"Feher, V. A. et al. A 3-dimensional trimeric beta-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram-negative bacterial porins. PLoS ONE 8, e68934 (2013).","journal-title":"PLoS ONE"},{"key":"312_CR27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4049\/jimmunol.138.2.575","volume":"138","author":"YX Zhang","year":"1987","unstructured":"Zhang, Y. X., Stewart, S., Joseph, T., Taylor, H. R. & Caldwell, H. D. Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis. J. Immunol. 138, 575\u2013581 (1987).","journal-title":"J. Immunol."},{"key":"312_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1099\/00221287-139-7-1565","volume":"139","author":"S Pal","year":"1993","unstructured":"Pal, S., Cheng, X., Peterson, E. M. & de la Maza, L. M. Mapping of a surface-exposed B-cell epitope to the variable sequent 3 of the major outer-membrane protein of Chlamydia trachomatis. J. Gen. Microbiol. 139, 1565\u20131570 (1993).","journal-title":"J. Gen. Microbiol."},{"key":"312_CR29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1128\/iai.61.4.1365-1370.1993","volume":"61","author":"Z Qu","year":"1993","unstructured":"Qu, Z., Cheng, X., de la Maza, L. M. & Peterson, E. M. Characterization of a neutralizing monoclonal antibody directed at variable domain I of the major outer membrane protein of Chlamydia trachomatis C-complex serovars. Infect. Immun. 61, 1365\u20131370 (1993).","journal-title":"Infect. Immun."},{"key":"312_CR30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1128\/iai.62.5.1576-1583.1994","volume":"62","author":"G Zhong","year":"1994","unstructured":"Zhong, G., Berry, J. & Brunham, R. C. Antibody recognition of a neutralization epitope on the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 62, 1576\u20131583 (1994).","journal-title":"Infect. Immun."},{"key":"312_CR31","unstructured":"Morrison, R. P., Manning, D. S. & Caldwell, H. D. in Sexually Transmitted Diseases Vol. 8 (ed. T.C. Quinn) 57\u201384 (Raven Press Ltd., 1992)."},{"key":"312_CR32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/0264-410X(93)90080-H","volume":"11","author":"H Su","year":"1993","unstructured":"Su, H. & Caldwell, H. D. Immunogenicity of a synthetic oligopeptide corresponding to antigenically common T-helper and B-cell neutralizing epitopes of the major outer membrane protein of Chlamydia trachomatis. Vaccine 11, 1159\u20131166 (1993).","journal-title":"Vaccine"},{"key":"312_CR33","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3389\/fimmu.2017.01652","volume":"8","author":"AW Olsen","year":"2017","unstructured":"Olsen, A. W., Lorenzen, E. K., Rosenkrands, I., Follmann, F. & Andersen, P. Protective effect of vaccine promoted neutralizing antibodies against the intracellular pathogen Chlamydia trachomatis. Front Immunol. 8, 1652 (2017).","journal-title":"Front Immunol."},{"key":"312_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1473-3099(19)30279-8","volume":"19","author":"S Abraham","year":"2019","unstructured":"Abraham, S. et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect. Dis. 19, 1091\u20131100 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"312_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1128\/iai.57.2.636-638.1989","volume":"57","author":"YX Zhang","year":"1989","unstructured":"Zhang, Y. X., Stewart, S. J. & Caldwell, H. D. Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants. Infect. Immun. 57, 636\u2013638 (1989).","journal-title":"Infect. Immun."},{"key":"312_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1084\/jem.175.1.227","volume":"175","author":"H Su","year":"1992","unstructured":"Su, H. & Caldwell, H. D. Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein. J. Exp. Med. 175, 227\u2013235 (1992).","journal-title":"J. Exp. Med."},{"key":"312_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003116","volume":"3","author":"EM Agger","year":"2008","unstructured":"Agger, E. M. et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3, e3116 (2008).","journal-title":"PLoS ONE"},{"key":"312_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.smim.2018.10.003","volume":"39","author":"GK Pedersen","year":"2018","unstructured":"Pedersen, G. K., Andersen, P. & Christensen, D. Immunocorrelates of CAF family adjuvants. Semin Immunol. 39, 4\u201313 (2018).","journal-title":"Semin Immunol."},{"key":"312_CR39","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1128\/iai.65.8.3065-3073.1997","volume":"65","author":"T Darville","year":"1997","unstructured":"Darville, T. et al. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect. Immun. 65, 3065\u20133073 (1997).","journal-title":"Infect. Immun."},{"key":"312_CR40","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/infdis\/158.3.661","volume":"158","author":"DW Megran","year":"1988","unstructured":"Megran, D. W., Stiver, H. G., Peeling, R., Maclean, I. W. & Brunham, R. C. Complement enhancement of neutralizing antibody to the structural proteins of Chlamydia trachomatis. J. Infect. Dis. 158, 661\u2013663 (1988).","journal-title":"J. Infect. Dis."},{"key":"312_CR41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.micinf.2016.07.002","volume":"18","author":"Z Yang","year":"2016","unstructured":"Yang, Z., Tang, L., Zhou, Z. & Zhong, G. Neutralizing antichlamydial activity of complement by chlamydia-secreted protease CPAF. Microbes Infect. 18, 669\u2013674 (2016).","journal-title":"Microbes Infect."},{"key":"312_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00409-17","volume":"85","author":"EK Naglak","year":"2017","unstructured":"Naglak, E. K., Morrison, S. G. & Morrison, R. P. Neutrophils are central to antibody-mediated protection against genital Chlamydia. Infect. Immun. 85, e00409-17 (2017).","journal-title":"Infect. Immun."},{"key":"312_CR43","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1128\/IAI.00749-16","volume":"84","author":"EK Naglak","year":"2016","unstructured":"Naglak, E. K., Morrison, S. G. & Morrison, R. P. IFNgamma is required for optimal antibody-mediated immunity against genital Chlamydia infection. Infect. Immun. 84, 3232\u20133242 (2016).","journal-title":"Infect. Immun."},{"key":"312_CR44","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/01.olq.0000216027.71144.74","volume":"33","author":"WM Geisler","year":"2006","unstructured":"Geisler, W. M., Suchland, R. J. & Stamm, W. E. Association of Chlamydia trachomatis serovar Ia infection with black race in a sexually transmitted diseases clinic patient population in Birmingham, Alabama. Sex. Transm. Dis. 33, 621\u2013624 (2006).","journal-title":"Sex. Transm. Dis."},{"key":"312_CR45","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1001\/jama.297.16.1784","volume":"297","author":"RJ Singleton","year":"2007","unstructured":"Singleton, R. J. et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297, 1784\u20131792 (2007).","journal-title":"JAMA"},{"key":"312_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1128\/JCM.01493-07","volume":"46","author":"CI Bandea","year":"2008","unstructured":"Bandea, C. I. et al. Chlamydia trachomatis serovars among strains isolated from members of rural indigenous communities and urban populations in Australia. J. Clin. Microbiol. 46, 355\u2013356 (2008).","journal-title":"J. Clin. Microbiol."},{"key":"312_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1099\/jmm.0.46262-0","volume":"55","author":"MC Hsu","year":"2006","unstructured":"Hsu, M. C. et al. Genotyping of Chlamydia trachomatis from clinical specimens in Taiwan. J. Med Microbiol. 55, 301\u2013308 (2006).","journal-title":"J. Med Microbiol"},{"key":"312_CR48","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1128\/JCM.42.4.1641-1647.2004","volume":"42","author":"M Lysen","year":"2004","unstructured":"Lysen, M. et al. Characterization of ompA genotypes by sequence analysis of DNA from all detected cases of Chlamydia trachomatis infections during 1 year of contact tracing in a Swedish County. J. Clin. Microbiol 42, 1641\u20131647 (2004).","journal-title":"J. Clin. Microbiol"},{"key":"312_CR49","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1128\/JB.186.8.2457-2465.2004","volume":"186","author":"K Millman","year":"2004","unstructured":"Millman, K. et al. Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States. J. Bacteriol. 186, 2457\u20132465 (2004).","journal-title":"J. Bacteriol."},{"key":"312_CR50","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/infdis\/166.6.1445","volume":"166","author":"KA Workowski","year":"1992","unstructured":"Workowski, K. A., Suchland, R. J., Pettinger, M. B. & Stamm, W. E. Association of genital infection with specific Chlamydia trachomatis serovars and race. J. Infect. Dis. 166, 1445\u20131449 (1992).","journal-title":"J. Infect. Dis."},{"key":"312_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/intimm\/dxp129","volume":"22","author":"S Minguet","year":"2010","unstructured":"Minguet, S., Dopfer, E. P. & Schamel, W. W. Low-valency, but not monovalent, antigens trigger the B-cell antigen receptor (BCR). Int Immunol. 22, 205\u2013212 (2010).","journal-title":"Int Immunol."},{"key":"312_CR52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1110\/ps.051616206","volume":"15","author":"Y Wang","year":"2006","unstructured":"Wang, Y. et al. Identification of surface-exposed components of MOMP of Chlamydia trachomatis serovar F. Protein Sci. 15, 122\u2013134 (2006).","journal-title":"Protein Sci."},{"key":"312_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2180-5-5","volume":"5","author":"HE Findlay","year":"2005","unstructured":"Findlay, H. E., McClafferty, H. & Ashley, R. H. Surface expression, single-channel analysis and membrane topology of recombinant Chlamydia trachomatis major outer membrane protein. BMC Microbiol. 5, 5 (2005).","journal-title":"BMC Microbiol"},{"key":"312_CR54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cyto.a.23353","volume":"93","author":"M Grasse","year":"2018","unstructured":"Grasse, M., Rosenkrands, I., Olsen, A., Follmann, F. & Dietrich, J. A flow cytometry-based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis. Cytom. A 93, 525\u2013532 (2018).","journal-title":"Cytom. A"},{"key":"312_CR55","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1128\/iai.60.6.2547-2550.1992","volume":"60","author":"JS Lin","year":"1992","unstructured":"Lin, J. S., Yan, L. L., Ho, Y. & Rice, P. A. Early complement components enhance neutralization of Chlamydia trachomatis infectivity by human sera. Infect. Immun. 60, 2547\u20132550 (1992).","journal-title":"Infect. Immun."},{"key":"312_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00430-020-00695-x","volume":"210","author":"M Lausen","year":"2020","unstructured":"Lausen, M. et al. Analysis of complement deposition and processing on Chlamydia trachomatis. Med Microbiol. Immunol. 210, 13\u201332 (2020).","journal-title":"Med Microbiol. Immunol."},{"key":"312_CR57","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1128\/iai.63.12.4704-4714.1995","volume":"63","author":"TW Cotter","year":"1995","unstructured":"Cotter, T. W. et al. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect. Immun. 63, 4704\u20134714 (1995).","journal-title":"Infect. Immun."},{"key":"312_CR58","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0264-410X(97)00206-5","volume":"15","author":"S Pal","year":"1997","unstructured":"Pal, S., Theodor, I., Peterson, E. M. & de la Maza, L. M. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 15, 575\u2013582 (1997).","journal-title":"Vaccine"},{"key":"312_CR59","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/mi.2015.125","volume":"9","author":"CP O\u2019Meara","year":"2016","unstructured":"O\u2019Meara, C. P. et al. Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia. Mucosal Immunol. 9, 1076\u20131088 (2016).","journal-title":"Mucosal Immunol."},{"key":"312_CR60","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1128\/iai.59.3.925-931.1991","volume":"59","author":"KH Ramsey","year":"1991","unstructured":"Ramsey, K. H. & Rank, R. G. Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. Infect. Immun. 59, 925\u2013931 (1991).","journal-title":"Infect. Immun."},{"key":"312_CR61","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.4049\/jimmunol.158.7.3344","volume":"158","author":"LL Perry","year":"1997","unstructured":"Perry, L. L., Feilzer, K. & Caldwell, H. D. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J. Immunol. 158, 3344\u20133352 (1997).","journal-title":"J. Immunol."},{"key":"312_CR62","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1046\/j.1365-3083.1997.d01-167.x","volume":"46","author":"M Johansson","year":"1997","unstructured":"Johansson, M., Schon, K., Ward, M. & Lycke, N. Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans? Scand. J. Immunol. 46, 546\u2013552 (1997).","journal-title":"Scand. J. Immunol."},{"key":"312_CR63","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.1128\/IAI.68.12.6979-6987.2000","volume":"68","author":"SG Morrison","year":"2000","unstructured":"Morrison, S. G., Su, H., Caldwell, H. D. & Morrison, R. P. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect. Immun. 68, 6979\u20136987 (2000).","journal-title":"Infect. Immun."},{"key":"312_CR64","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.4049\/jimmunol.0900295","volume":"183","author":"DC Gondek","year":"2009","unstructured":"Gondek, D. C., Roan, N. R. & Starnbach, M. N. T cell responses in the absence of IFN-gamma exacerbate uterine infection with Chlamydia trachomatis. J. Immunol. 183, 1313\u20131319 (2009).","journal-title":"J. Immunol."},{"key":"312_CR65","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.4049\/jimmunol.1103032","volume":"189","author":"DC Gondek","year":"2012","unstructured":"Gondek, D. C., Olive, A. J., Stary, G. & Starnbach, M. N. CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. J. Immunol. 189, 2441\u20132449 (2012).","journal-title":"J. Immunol."},{"key":"312_CR66","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1086\/432070","volume":"192","author":"CR Cohen","year":"2005","unstructured":"Cohen, C. R. et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma. J. Infect. Dis. 192, 591\u2013599 (2005).","journal-title":"J. Infect. Dis."},{"key":"312_CR67","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/infdis\/173.6.1437","volume":"173","author":"J Kimani","year":"1996","unstructured":"Kimani, J. et al. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. J. Infect. Dis. 173, 1437\u20131444 (1996).","journal-title":"J. Infect. Dis."},{"key":"312_CR68","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.4049\/jimmunol.157.10.4554","volume":"157","author":"L Ortiz","year":"1996","unstructured":"Ortiz, L. et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J. Immunol. 157, 4554\u20134567 (1996).","journal-title":"J. Immunol."},{"key":"312_CR69","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1128\/IAI.68.3.1719-1723.2000","volume":"68","author":"L Ortiz","year":"2000","unstructured":"Ortiz, L., Angevine, M., Kim, S. K., Watkins, D. & DeMars, R. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans. Infect. Immun. 68, 1719\u20131723 (2000).","journal-title":"Infect. Immun."},{"key":"312_CR70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1574-695X.2000.tb01409.x","volume":"27","author":"M Ikehata","year":"2000","unstructured":"Ikehata, M., Numazaki, K. & Chiba, S. Analysis of Chlamydia trachomatis serovars in endocervical specimens derived from pregnant Japanese women. FEMS Immunol. Med. Microbiol. 27, 35\u201341 (2000).","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"312_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54886-5","volume":"9","author":"I Lesiak-Markowicz","year":"2019","unstructured":"Lesiak-Markowicz, I., Schotta, A. M., Stockinger, H., Stanek, G. & Markowicz, M. Chlamydia trachomatis serovars in urogenital and ocular samples collected 2014-2017 from Austrian patients. Sci. Rep. 9, 18327 (2019).","journal-title":"Sci. Rep."},{"key":"312_CR72","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fimmu.2017.00569","volume":"8","author":"JE Wern","year":"2017","unstructured":"Wern, J. E., Sorensen, M. R., Olsen, A. W., Andersen, P. & Follmann, F. Simultaneous subcutaneous and intranasal administration of a CAF01-adjuvanted Chlamydia vaccine elicits elevated IgA and protective Th1\/Th17 responses in the genital tract. Front Immunol. 8, 569 (2017).","journal-title":"Front Immunol."},{"key":"312_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0157-x","volume":"5","author":"N Nguyen","year":"2020","unstructured":"Nguyen, N. et al. Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge. NPJ Vaccines 5, 7 (2020).","journal-title":"NPJ Vaccines"},{"key":"312_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076176","volume":"8","author":"KM Fahrbach","year":"2013","unstructured":"Fahrbach, K. M., Malykhina, O., Stieh, D. J. & Hope, T. J. Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS ONE 8, e76176 (2013).","journal-title":"PLoS ONE"},{"key":"312_CR75","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1128\/iai.39.3.1491-1494.1983","volume":"39","author":"RC Brunham","year":"1983","unstructured":"Brunham, R. C., Kuo, C. C., Cles, L. & Holmes, K. K. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect. Immun. 39, 1491\u20131494 (1983).","journal-title":"Infect. Immun."},{"key":"312_CR76","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3389\/fimmu.2015.00628","volume":"6","author":"E Lorenzen","year":"2015","unstructured":"Lorenzen, E. et al. Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis. Front Immunol. 6, 628 (2015).","journal-title":"Front Immunol."}],"updated-by":[{"DOI":"10.1038\/s41541-022-00521-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000}}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00312-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:16:22Z","timestamp":1698916582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00312-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["312"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00312-9","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41541-022-00521-w","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41541-022-00521-w","URL":"https:\/\/doi.org\/10.1038\/s41541-022-00521-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. A.W.O., I.R., P.A., and F.F. are co-inventors on a patent application relating to <i>C.t<\/i>. vaccines. All rights have been assigned to Statens Serum Institut, a Danish not-for-profit governmental institute. A.W.O., I.R., P.A., and F.F. are employees at Statens Serum Institut. M.J.H. is an employee of London School of Hygiene & Tropical Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}